Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.35 |
| ▸ | SARS1 | P49591 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362480 | 1.00 | ADORA2A (0.37) | ADORA2AADORA3ADORA1STING1SARS1 | |
| SCHEMBL27419759 | 0.91 | ADORA2A (0.36) | ADORA2AADORA3ADORA1STING1SARS1 | |
| SCHEMBL6403262 | 0.87 | ADORA2A (0.38) | ADORA2AADORA3ADORA1STING1SARS1 | |
| SCHEMBL8939099 | 0.86 | STING1 (0.38) | ADORA2AADORA3STING1ADORA2B | |
| SCHEMBL5963251 | 0.86 | STING1 (0.38) | ADORA2AADORA3STING1ADORA2B | |
| SCHEMBL8939101 | 0.86 | STING1 (0.38) | ADORA2AADORA3STING1ADORA2B | |
| SCHEMBL16392689 | 0.83 | ADORA2A (0.34) | ADORA2AADORA3ADORA1SARS1ADORA2B | |
| SCHEMBL22559797 | 0.83 | ADORA2A (0.34) | ADORA2AADORA3ADORA1SARS1ADORA2B | |
| SCHEMBL18061767 | 0.81 | ACHE (0.41) | ADORA3STING1 | |
| SCHEMBL19827872 | 0.81 | ACHE (0.41) | ADORA3STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | UMPS, PNP, NUDT1 | ADORA2A 543/4885ADORA3 814/4885ADORA1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.